FMP
Millendo Therapeutics, Inc.
MLND
NASDAQ
Inactive Equity
Millendo Therapeutics, Inc., a late-stage biopharmaceutical company, focuses on developing novel treatments for orphan endocrine diseases in the United States. Its lead product candidates include livoletide, a potential treatment for Prader-Willi syndrome; nevanimibe, a potential treatment for patients with classic congenital adrenal hyperplasia; and MLE-301, a neurokinin 3-receptor antagonist for the treatment of vasomotor symptoms in menopausal women. The company is headquartered in Ann Arbor, Michigan.
1.06 USD
-0.06000006 (-5.66%)
2019
2020
2021
2022
2023
2024
2025
2026
2027
2028
1.56B
1.29B
1.17B
1.08B
1.06B
968.65M
881.74M
802.62M
730.61M
665.06M
-63.85M
-29.78M
-111.53M
-87.16M
3.56M
-45.93M
-41.81M
-38.06M
-34.64M
-31.54M
-20.54M
-15.49M
-16.53M
-21.96M
-11.89M
-13.73M
-12.5M
-11.38M
-10.35M
-9.43M
-84.39M
-45.27M
-128.06M
-109.13M
-8.34M
-59.66M
-54.31M
-49.43M
-45M
-40.96M
12.6
12.6
12.6
12.6
12.6
-52.99M
-42.84M
-34.63M
-28M
-22.63M
-181.09M